lower ep reduc ep
temper revenu gallipr entyc outward
pipelin shift felin pain dcf-deriv target price move
lower view
detail base increment confer call file disclosur
model assum sequenti lower entyc revenu distributor stock
entyc revenu though remain optimist long-
term trajectori model also assum petx recogn million
gallipr sale mileston addit million gallipr
mileston million transfer manufactur third parti
supplier million ad inflamm claim european label
note million elanco licens liabil due come book
decemb potenti sourc upsid model await
reiter outperform petx share drop wednesday
channel stock lack immedi pipelin promis overshadow
rel respect adopt trend three commerci offer
maintain posit view risk includ regulatori headwind
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
petx companion anim therapeut compani focus
licens develop commerci biopharmaceut
product companion anim
blue sky scenario assum higher peak sale key
product includ gallipr nocita entyc acceler
timelin addit product launch greater probabl
success meaning competit core product
grey sky scenario assum lower peak sale
key product current model meaning
contribut addit product develop well
potenti liquid profit issu
price rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
compani mention price
